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Abstract 
Background and Aim: Severe left ventricular dysfunction patients with ejection fraction ≤ 30% are at a higher 
risk for complications and mortality than patients with ejection fraction >30%. The death of cardio-myocytes at 
injured regions leads to myocardium dysfunction. Bone marrow-derived mesenchymal stem cells are 
undifferentiated cells that have been used for the regeneration of damaged cardio-myocytes. Due to the inherent 
capability of mesenchymal stem cells to improve cardiac functions, in this research, our objective was to explore 
the possible association of the mesenchymal stem cells proliferation rate with Coronary Artery Bypass Grafting 
outcomes in patients with severe left ventricular dysfunction after off-pump Coronary Artery Bypass Grafting. 
Methods: For investigating the possible association of mesenchymal stem cells proliferation with Coronary Artery 
Bypass Grafting outcomes (ejection fraction, hypertension risk, and the time of hospital stay), we collected bone 
marrow samples from 30 patients (18 men and 12 women) who underwent off-pump Coronary Artery Bypass 
Grafting at Afshar Hospital and Seyed Al-Shohada Hospital (Yazd, Iran). Mesenchymal stem cells were isolated 
and cultured; then, cells were counted after 4, 7, and 14 days using trypan-blue color, and doubling times were 
calculated. Results: There was an association between doubling time and ejection fraction after surgery. 
Ejection fraction in postoperative patients increased, but this association was not significant. Also, our study 
showed that the risk of hypertension is equal in male and female patients. There were no significant differences 
in mesenchymal stem cells doubling time with hypertension and the time of hospital stay in the ICU. 
Conclusion: Based on this study, we concluded that there was no significant relationship between the rate of 
mesenchymal stem cell proliferation and Coronary Artery Bypass Grafting outcomes in patients with severe left 
ventricular dysfunction. 
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Introduction 
Severe left ventricular dysfunction has become very 
common in patients with ischemic cardiomyopathy 
and remains a remarkable risk factor for mortality 
and morbidity (1). Ejection fraction ≤ 30% has been 
selected as the cut-off point for severe left 
ventricular dysfunction (2). In ischemic 
circumstances, the death of cardio-myocytes at 
injured regions leading to myocardium dysfunction 
and necrosis (3, 4). Currently, Coronary Artery 
Bypass Grafting (CABG) is considered a standard 
treatment in patients with low ejection fraction (5). 
However, the therapeutic effects of CABG surgery 
in these patients are not easily predictable (6).  
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Furthermore, CABG does not restore the necrotic 
cells of injured heart tissues but only manages the 
clinical symptoms of the disease (1). In recent 
decades, many studies have proceeded to explore 
cells with the ability to differentiate and repair the 
damaged myocardium (7). Cells isolated from a 
wide variety of embryonic and adult tissues have 
been investigated for the regeneration and 
management of injured heart tissue (7-9). Among 
them, Human Bone Marrow Mesenchymal Stem 
Cells (BMSCs) have been particularly attractive 
because of their potential to differentiate into 
cardiomyocytes and coronary vessels (10). In a cell 
culture laboratory, isolated Mesenchymal Stem 
Cells (MSCs) were successfully differentiated into 
cardiomyocytes and characterized by cardiac 
markers expression (11). Several in vivo studies 
suggested that bone marrow-derived MSCs may be 
critically implicated in the protection of the 
structural and the improvement of myocardium 
function (10, 12, 13). Due to the importance of 
BMSCs in the repair of the cardiac structure and 
function, BMSCs may be related to CABG 
outcomes in patients with severe left ventricular 
dysfunction after off-pump CABG (14). In the 
present study, we examined the possible effects of 
MSCs in patients with severe left ventricular 
dysfunction (ejection fraction ≤ 30%) after off-
pump bypass surgery and the improvement in 
ventricular performance. After CABG, the 
relationships between the doubling time of MSCs 
and ejection fraction, hypertension risk, and the 
hospital stay period were examined.  
Methods 
Patients and Study Design 
The study protocol was approved by the Ethics 
Committee of Shahid Sadoughi University of 
Medical Sciences, and patients' consent was filled 
before entry to study. We enrolled 30 patients 
undergoing off-pump left ventricular CABG, who 
were referred to as Afshar and Seyed Al-Shohada 
Hospitals (Yazd, Iran). The inclusion criteria were 
as follows: patients with severe left ventricular 
dysfunction (ejection fraction < 30%). The 
exclusion criteria were as follows: ejection 
fraction > 30, patients with concomitant diseases 
such as severe valvular heart disease, diabetes, and 
infectious diseases. Then, the necessary tests, such 
as echocardiography, were evaluated by a 
physician. One cc bone marrow sample per patient 
was aspirated from the sternum during off-pump 
CABG and then transferred to a stem cell laboratory 
for isolation of MSCs and further evaluation. 
Culture of human BMSCs 
Bone marrow samples (1mL) were obtained from 
the sternum during off-pump CABG. For the MSCs 
isolation from bone marrow, the aspirated bone 
marrow samples were diluted with αMEM cell 
culture medium containing 20% fetal bovine serum 
(FBS). In the laboratory, samples were transferred 
to 15 mL Falcons and then centrifuged at 
12000 rpm for 5 minutes. After centrifugation, the 
supernatant was removed. The cells were grown in 
αMEM culture medium containing 20% FBS in an 
incubator containing 5% CO2 at 37°C. For the 
Characterization of MSCs, the presence of surface 
markers of Hematopoietic Stem Cells (HSCs)  
(CD34, CD45) and MSCs (CD90, CD105) was 
evaluated by a flow cytometer (FACS Calibur 
Becton, Dickinson, USA).  
Population-doubling time 
For doubling time calculation, the cells were 
cultured in an αMEM supplemented with 20% FBS 
and incubated at 37°C until arriving at 80% 
confluence. Then, cells were trypsinized, and the 
cell numbers were counted in 4, 7, and 14 days 
using trypan blue and hemocytometer. The 
relationships between the doubling time of MSCs 
/ejection fraction and between hypertension risk/ 
the hospitalization were examined. The 
relationships between MSCs doubling time/ejection 
fraction and between the risk of high blood 
pressure/the hospitalization period were examined. 
Statistical analysis: The Graphpad Prism Version 8 
software (GraphPad Software, San Diego, CA, 
USA) was used to analyze results. All data 
presented as means ± standard deviations. The 
results were analyzed by unpaired t-test.  
Results 
In this study, 18 men and 12 women with severe 
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left ventricular dysfunction were studied. In all 30 
patients, 1 ml bone marrow from the sternum was 
collected during surgery for BMSCs isolation and 
doubling time calculation. The isolation of the 
MSCs was confirmed via flowcytometry method. 
MSCs express CD90 and CD105 markers. Also, 
these cells were negative for hematopoietic 
markers, CD34, and CD45 (data were not shown). 
MSCs' phenotype was shown in Figure 1. 
 
 
Figure 1. MSCs after extraction and culture. 
The relationship between preoperative ejection 
fraction and the doubling time of BMSCs  
Figure 2A shows the mean of preoperative 
ejection fraction. There was no significant 
difference in the percentage of ejection fraction in 
men and women. The mean ± deviation was 
44.64 ± 2.5 in the male group and 43 ± 2.2 in the 
female group. Figure 2B shows the relationship 
between ejection fraction in male and female 
patients with a doubling time of BMSCs before 
CABG. There was no significant relationship 
between preoperative ejection fraction and MSCs 
doubling time (r2=0.0188).  
The relationship between postoperative ejection 
fraction and the doubling time of BMSCs 
Figure 3A shows the mean of postoperative 
ejection fraction in men and women. There was no 
significant difference in the percentage of ejection 
fraction in males and females, and the mean ± 
deviation was 46 ± 2.8 in the male group and 45.4 
± 2.1 in the female group. Figure 3B shows the 
relationship between ejection fraction in male and 
female patients with BMSCs doubling time after 
CABG. There was no significant relationship 
between preoperative ejection fraction and MSCs 
doubling time (r2=0.0252). 
Relationship between the hospitalization period 
and BMSCs doubling-time 
Figure 4A shows the mean of hospitalization 
period in male and female patients in the ICU 
(day). We found no significant difference between 
the mean hospitalization period in the ICU in men 
and women, and the mean ± SD was 8.1 ± 2.8 in 
the male group and 8.5 ± 5 in the female group. 
Figure 4B shows the relationship between the 
hospitalization period in male and female patients 
with a BMSCs doubling time after CABG. There 
was no significant relationship between hospital 
stay time in the ICU and MSCs doubling time 
(r2=0.034). 
Relationship between hypertension and doubling 
time of BMSCs 
Figure 5A shows that among 18 male patients in 
this study, ten patients had hypertension, while 
among 12 female patients in this study, five 
patients suffer hypertension. Therefore, the 
percentage of women and men with hypertension 
did not differ. The odds ratio was 1, meaning that 
the chances of hypertension in male and female 
patients were equal. Figure 5B illustrates that there 
was no considerable difference in BMSCs 
doubling time in female patients with hypertension 
risk (196 ± 55) and male patients with 
hypertension risk (238 ± 93). On the other hand, 
there was no significant difference between 
BMSCs doubling time in males (224 ± 47) and 
female (205 ± 61) patients without hypertension. 
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Figure 2. A) The relationship between gender and preoperative ejection fraction. The data is shown as a 
mean ± standard deviation B) the relationship between preoperative ejection fraction (EF) and BMSCs doubling time. 
 
Figure 3. A) The relationship between gender and postoperative ejection fraction. The data is shown as a 
mean ± standard deviation. B) The relationship between postoperative ejection fraction (EF) and BMSCs doubling 
time. 
 
Figure 4. A) The relationship between gender and hospital stay in the ICU (day) B) The relationship between 
hospitalization period in the ICU and BMSCs doubling time. 
Association between Characterizations of Bone Marrow …                                                           Esmailidehaj M, et al. 
Archives of Medical Laboratory Sciences; Volume 5, No. 4, Fall 2019  34 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License 
 
Figure 5. A) Relationship between hypertension in male and female patients. B) Relationship between doubling time 
of BMSCs in patients with hypertension. Data were presented using a two-way ANOVA statistical test and 
mean ± standard deviation. 
 
Discussion 
The main findings of our study can be summarized 
as follows: no significant differences were found 
between BMSCs doubling time and any of these 3 
CABG outcomes: ejection fraction, hypertension 
risk, and the time of hospital stay in patients with 
severe left ventricular dysfunction after off-pump 
CABG.  
According to the American Society of 
Echocardiography's Guidelines and Standards 
Committee, severe left ventricular dysfunction has 
been described with an ejection fraction of less than 
30% (2). Many clinical kinds of research have 
shown relevant evidence that patients with an 
ejection fraction < 30% are at higher death risk than 
patients with ejection fraction > 30% (15). In the 
last decade, stem cell therapy has been used as a 
new option for the repair of damaged myocardium 
and the improvement of cardiac function (16-18). 
Several in vitro and in vivo studies have confirmed 
the capability of human BMSCs to differentiate into 
the cardio-myocytes (3). In 2016, Valentina et al. 
reported that the ability of stem cells to proliferation 
and differentiation decreased with aging. They also 
reported that the ability of MSC to regenerate 
damaged tissues such as myocardium is relevant to 
their paracrine ability and not to their ability to 
differentiate into cardiomyocytes (19-21). Due to 
the importance of BMSCs in tissue repair and 
regeneration, the features of BMSCs may be related 
to CABG outcomes in patients with severe left 
ventricular dysfunction after off-pump CABG. In 
the current study, MSCs were isolated from 
aspirated sternum bone marrow of patients 
undergoing CABG, using a small aspiration needle. 
Consistent with previous reports, isolated MSCs 
expressed positive markers CD90, and CD105, but 
did not show negative markers CD34 and CD45 
(22-24). Then, we investigated the possible 
association between isolated MSCs doubling time 
and ejection fraction, risk of hypertension, and the 
hospitalization period in patients with severe left 
ventricular dysfunction (ejection fraction ≤ 30%) 
after off-pump bypass surgery. There was no 
significant relationship between the doubling time 
of MSCs and preoperative ejection fraction. There 
is an association between doubling time and 
ejection fraction after surgery. After surgery, the 
ejection fraction was increased, but this association 
was not significant. Any similar study has not yet 
examined the relationship between hospitalization 
and MSC characteristics. Here, the relationship 
between hospitalization period and MSC doubling 
time was investigated, but no remarkable 
relationship was obtained between the patient 
hospitalization period in ICU and MSC doubling 
time.  
In hypertensive rats, intravenous injection of MSCs 
reduces the pressure on the ventricles and the 
symptoms of hypertension. MSCs can increase the 
gene expression of nitric oxide synthase (NOS) and 
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reduce the average blood pressure by producing 
endothelial progenitors (25). Therefore, due to the 
MSCs' potential capability to improve hypertension 
and its symptoms, we investigated the relationship 
between the MSCs' doubling time and the 
hypertension risk in patients. Our study suggested 
that hypertension risk is equal in male and female 
patients. There were no noticeable differences in 
BMSCs female patients with and without 
hypertension, as well as male patients with and 
without hypertension. The lack of a significant 
association between hypertension and doubling 
time can be attributed to the patients aging (50-70 
years).  
Conclusion 
Despite the role of MSCs in the repair of damaged 
cardiac tissue, the results of the present study 
claimed that there was not a clear relationship 
between the rate of MSCs proliferation and CABG 
outcomes (ejection fraction, hypertension risk, and 
the time of hospital stay) in patients with severe left 
ventricular dysfunction. It is recommended that this 
study be performed on a larger specimen group.  
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